TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$168.06 USD
+1.41 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $168.81 +0.75 (0.45%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$168.06 USD
+1.41 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $168.81 +0.75 (0.45%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
Zacks News
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
by Zacks Equity Research
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.
Paragon 28 (FNA) Expands SMART 28 Ecosystem With New Launches
by Zacks Equity Research
Paragon 28 (FNA) strengthens its position in the foot and ankle device market with the launch of the SMART28 Case Management Portal and the SMART Bun-Yo-Matic device.
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.
Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
by Zacks Equity Research
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
by Zacks Equity Research
Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.
Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook
by Zacks Equity Research
Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.
Should Quest Diagnostics (DGX) be in Your Portfolio Now?
by Zacks Equity Research
Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.
TransMedics (TMDX) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Can TransMedics (TMDX) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
New Strong Buy Stocks for August 2nd
by Zacks Equity Research
SVM, IBCP, TMDX, WT and YELP have been added to the Zacks Rank #1 (Strong Buy) List on August 2, 2024.
Compared to Estimates, TransMedics (TMDX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TransMedics (TMDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 66.67% and 15.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street's Insights Into Key Metrics Ahead of TransMedics (TMDX) Q2 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Are You Looking for a Top Momentum Pick? Why TransMedics (TMDX) is a Great Choice
by Zacks Equity Research
Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will TransMedics (TMDX) Gain on Rising Earnings Estimates?
by Zacks Equity Research
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
by Zacks Equity Research
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.